This bill matters because it shifts the balance between encouraging drug innovation for rare diseases and controlling drug costs. If this bill becomes law, pharmaceutical companies developing drugs for rare conditions (including those that treat more than one rare disease) will have a longer period during which their drug prices cannot be negotiated by the government. This could motivate companies to invest more in these specialized treatments, potentially leading to more options for patients with rare diseases.

However, it also means that the government's ability to lower drug costs for Medicare beneficiaries and taxpayers through price negotiation would be limited for an expanded category of drugs, and for a longer time. This could result in higher expenditures for these specific medicines for a more extended period compared to what would happen if the bill does not pass, impacting healthcare budgets and potentially patient access or out-of-pocket costs.